ArticleAntimicrobial agents and chemotherapy2023
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Review
- Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.Antimicrobial agents and chemotherapy · 2026Article
- TDM-Guided Dalbavancin Treatment for ComplexAntibiotics (Basel, Switzerland) · 2026Article
- Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing.Antimicrobial agents and chemotherapy · 2026Article
- Study of the release kinetics of dalbavancin from bone allografts.Journal of materials science. Materials in medicine · 2025Article
- Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.Antimicrobial agents and chemotherapy · 2025Article
- Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.Indian journal of microbiology · 2025Article
- Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment.Antibiotics (Basel, Switzerland) · 2025Article
- Model-Informed Precision Dosing of Levamlodipine Besylate in Smoking Patients.Drug design, development and therapy · 2025Observational
- Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Off-label use of dalbavancin in children: a case series.The Journal of antimicrobial chemotherapy · 2024Article
- Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.Antimicrobial agents and chemotherapy · 2024Article
- Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.Infectious diseases and therapy · 2024Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.Antibiotics (Basel, Switzerland) · 2023Article
- Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin.Infectious diseases and therapy · 2023Article
- Dalbavancin in Bone and Joint Infections: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.